Harvoni

Chemical Nameledipasvir/sofosbuvir
Dosage FormTablet (oral; ledipasvir/sofosbuvir (90mg/400mg, 45mg/ 200mg)); Pellet (oral; ledipasvir/sofosbuvir (45mg/200mg, 33.75mg/150mg))
Drug ClassInhibitors
SystemBlood
CompanyGilead Sciences Inc.
Approval Year2014

Indication

  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 or 4 infection who are liver transplant recipients without.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Harvoni (ledipasvir and sofosbuvir) Prescribing Information2019Gilead Sciences, Inc., Foster City, CA